RenovoRx, Inc.
Close on Oct 19, 2026
- Market cap
- $54.87M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $909.00K | $-0.06 | $-0.05 |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $563.00K | $-0.09 | $-0.08 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.08 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $422.00K | $-0.08 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $197.00K | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 17, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 2, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | full-year 2026 | $3.75M to $4.25M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements RenovoRx filed with the SEC
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Results of operations · EX-99.1 to Form 8-K/A
to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August
Other events · EX-99.1 to Form 8-K
RenovoRx Reports Record First Quarter 2026:
Results of operations · EX-99.1 to Form 8-K
Reports Full Year 2025 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Announces $10 Million at Market Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results, Including Approximately
Results of operations · Other events · EX-99.1 to Form 8-K
Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation
Results of operations · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Reports Initial Revenues from RenovoCath ® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC
Results of operations · Other events · EX-99.1 to Form 8-K
VIEW, Calif.—(BUSINESS WIRE)— RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life
Material agreement · Other events · EX-99.1 to Form 8-K
RenovoRx Announces Pricing of $12.1 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Reports Third Quarter 2024 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
Increases Production of FDA-Cleared RenovoCath ® Delivery System in Response to Strong Demand from Oncology and Interventional
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Closes $11.1 Million Private Placement,
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces $11.1 Million At Market Private Placement
Material agreement · Other events · EX-99.1 to Form 8-K
RenovoRx Closes $6.1 Million Private Placement
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
RenovoRx Reports Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Reports First Quarter 2023 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Results of operations · Other events · EX-99.1 to Form 8-K
Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem TM Supports Potential for RenovoTAMP ®
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Appoints Angela Gill Nelms as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Appoints James Ahlers as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Full Year 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K